Spedra contains avanafil, a selective phosphodiesterase-type-5 (PDE5) inhibitor, and is used to treat erectile dysfunction. Avanafil should be taken 30 minutes before sexual activity and has a rapid onset of action.
In clinical studies, Spedra increased the share of successful sexual intercourses by 20-30% compared with placebo. This is comparable with other PDE5 inhibitors, but head to head studies have not been conducted.
PDE5 inhibitors primarily differ in the way food affects absorption and in the duration of action, and thus it is the patient's preferences in relation to these factors, which, along with the treatment price, are essential for the choice of drug. The drugs also differ in their degree of blockage of the other types of phosphodiesterase enzymes and thus the safety profile: visual disturbances for sildenafil and vardenafil and back pain for tadalafil. Generally, the adverse events of avanafil are mild and well-tolerated.
Due to the high treatment price compared to sildenafil, it is IRF's overall assessment that Spedra should not be first-line treatment; it may be used if a satisfactory effect has not been achieved with sildenafil.
Spedra was marketed on 4 August 2014.